Vol. 7, Issue 2, Part H (2025)

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, chronic musculoskeletal pain and stress urinary incontinence (in some regions). This review summarizes mechanism, pharmacokinetics, major clinical evidence across indications, safety profile, dosing considerations and recent regulatory concerns. Key randomized controlled trials and meta-analyses support duloxetine’s efficacy for mood disorders and multiple pain syndromes, while the safety profile requires monitoring for hepatic injury, blood pressure changes, serotonin syndrome risk and discontinuation symptoms.